Myriad Decision Made

A federal appeals court has ruled that genes can be patented, and upheld Myriad Genetics' patents for the BRCA1 and BRCA2 genes, reports The New York Times' Andrew Pollack. Myriad uses the genes as the basis for its BRCAnalysis diagnostic test to detect mutations in the BRCA genes. In March 2010, New York Southern District Court Judge Robert Sweet invalidated the patents and said that genes can't be patented because they are products of nature.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.